Free Trial
→ Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets) (Ad)tc pixel
NASDAQ:MTVA

MetaVia Q2 2025 Earnings Report

MetaVia logo
$1.88 -0.14 (-6.72%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

MetaVia EPS Results

Actual EPS
-$2.86
Consensus EPS
-$3.52
Beat/Miss
Beat by +$0.66
One Year Ago EPS
N/A

MetaVia Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MetaVia Announcement Details

Quarter
Q2 2025
Date
8/7/2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

MetaVia's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

MetaVia's Q2 2025 Press ReleasePress Release
(8-K)
MetaVia's Q2 2025 Quarterly reportQuarterly report
(10-Q)

MetaVia Earnings Headlines

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
June 9 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308704/0/en/biostem-technologies-announces-appointment-of-three-new-members-to-its-board-of-directors.html
MetaVia Shareholders Approve Equity Plan and Reverse Split
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/metavia-shareholders-approve-equity-plan-and-reverse-split?utm_source=marketbeat.com&utm_medium=referral
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.tc pixel
June 12 at 1:00 AM  |  InvestPub (Ad)
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/metavia-presents-new-late-breaking-obesity-and-metabolic-data-at-the-ada-2026-scientific-sessions-supporting-da-1726-differentiation-and-vanoglipel-combination-potential-302793358.html
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
June 4, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302790822.html
MTVA: No evidence for changes in cardiovascular parameters in phase 1 trial of DA-1726
May 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/mtva-no-evidence-for-changes-in-cardiovascular-parameters-in-phase-1-trial-of-da-1726/ar-AA24hULB
See More MetaVia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email.

About MetaVia

MetaVia (NASDAQ:MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

View MetaVia Profile
Earnings Tools